Confusion over Article 8.
作者信息
Tambuyzer Erik
出版信息
EMBO Rep. 2005 Aug;6(8):690. doi: 10.1038/sj.embor.7400485.
Abstract
摘要
相似文献
1
Confusion over Article 8.
EMBO Rep. 2005 Aug;6(8):690. doi: 10.1038/sj.embor.7400485.
2
Adopting an orphan.
EMBO Rep. 2005 Jun;6(6):507-10. doi: 10.1038/sj.embor.7400450.
3
Regulators adopt more orphan drugs.
Nature. 2014 Apr 3;508(7494):16-7. doi: 10.1038/508016a.
4
Policy alternatives for treatments for rare diseases.
CMAJ. 2010 Nov 23;182(17):E787-92. doi: 10.1503/cmaj.081429. Epub 2010 Jul 12.
5
Time to revisit the orphan drug law.
Eur J Clin Pharmacol. 2012 Feb;68(2):113. doi: 10.1007/s00228-011-1115-3. Epub 2011 Aug 13.
6
Rare disease resources not as rare as one might think.
Am J Health Syst Pharm. 2013 Jun 15;70(12):1013-4. doi: 10.2146/ajhp130071.
7
Why we should care about ultra-rare disease.
Eur Respir Rev. 2016 Jun;25(140):101-3. doi: 10.1183/16000617.0017-2016.
8
Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
Orphanet J Rare Dis. 2011 Sep 27;6:62. doi: 10.1186/1750-1172-6-62.
9
Orphan drugs revisited.
QJM. 2006 May;99(5):341-5; discussion 350-1. doi: 10.1093/qjmed/hcl033. Epub 2006 Feb 27.
10
Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
Orphanet J Rare Dis. 2011 Sep 5;6:59. doi: 10.1186/1750-1172-6-59.
本文引用的文献
1
Adopting an orphan.
EMBO Rep. 2005 Jun;6(6):507-10. doi: 10.1038/sj.embor.7400450.
Zotero 插件